Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 7,024 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Volunteers. Clear all

Conditions: Thrombosis
Interventions: Kcentra, Apixaban, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: TEG 6s Citrated K, KH, RTH, and FFH Cartridge, Clauss Fibrinogen; Diagnostic Test
Lead sponsor: Haemonetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Oakland, California • Maywood, Illinois • New Orleans, Louisiana

Conditions: Healthy Volunteers
Interventions: Midazolam, AZD1722, AZD1722 and Midazolam; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Dyslipidemia, Healthy Volunteers
Interventions: TAP311; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Healthy Subjects
Interventions: repeated transcranial magnetic stimulation; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: PF-06882961 20MG; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Obstetric Labour, Premature, Premature Labor
Interventions: GSK221149A; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Basal Blood Flow
Interventions: Quest Hyperspectral Imaging System; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: Lutikizumab Dose A, Lutikizumab Dose B; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Cypress, California • Grayslake, Illinois • Austin, Texas

Conditions: Alzheimer's Disease
Interventions: LY2062430, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 3 more

Conditions: Chronic Hepatitis B Infections
Interventions: Pevifoscorvir Sodium (ALG-000184); Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Dental Pain
Interventions: Pre-Op pregabalin, Pre-Op Placebo 1, Post-Op pregabalin, Post-Op Placebo 1, Post-Op Placebo 2, Post-Op acetaminophen; Drug
Lead sponsor: Nevakar, Inc.; Industry
Eligibility: 17 Years to 55 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232, Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: DSP loaded RBC using EryDex System, Sham treated RBC using the EryDex System; Drug
Lead sponsor: Quince Therapeutics S.p.A.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pneumonic Plague, Preventive Therapy
Interventions: rF1V vaccine; Biological
Lead sponsor: DynPort Vaccine Company LLC, A GDIT Company; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy Volunteer, HV
Interventions: AMA1-C1/Alhydrogel + CpG 7909; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Bethesda, Maryland • Rochester, New York

Conditions: Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Interventions: CF-301, Placebo; Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: Lenexa, Kansas • Omaha, Nebraska

Conditions: Healthy
Interventions: Cholestyramine, Colesevelam HCl; Drug
Lead sponsor: Louisville Metabolic and Atherosclerosis Research Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions: RVX000222, Placebo; Drug
Lead sponsor: Resverlogix Corp; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Kidney Injury (Nontraumatic)
Interventions: CXA-10 emulsion, Placebo; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Healthy Volunteers, Body Weight
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 20 Years to 50 Years · Female only
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: Cenobamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: E2730, E2730-matched placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Healthy
Interventions: Fexofenadine Tablets 180 mg, Allegra® Tablets 180 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Search by objective public record fields.

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

TMS Modulation of Insula-related Brain Networks

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

Absorption, Distribution, Metabolism And Excretion Study For GSK221149A

A Study of a Device Used to Take Pictures of Skin Blood Flow

Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Dental Pain Study of Analgesics in Patients Undergoing Molar Removal

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

Recovery and Survival of EryDex in Non-patient Volunteers

Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

Study of CXA-10 in Healthy Volunteers

Weight Management Interactions in a Virtual Clinical Environment

A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg